Reports say that the President expressed strong interest in creating a universal influenza vaccine in a recent meeting with Bill Gates

WASHINGTON- Following reports that the President expressed strong interest in the creation of a universal influenza vaccine in a recent meeting with Bill Gates, U.S. Senators Amy Klobuchar and Edward Markey (D-MA) were joined by Senators Tammy Baldwin (D-WI), Richard Blumenthal (D-CT), Bill Nelson (D-FL), Angus King (I-ME) and Chris Van Hollen (D-MD) in calling on him to support legislation that would invest in research to help create a universal flu vaccine. Earlier this year, the Senators introduced the Flu Vaccine Act which would authorize additional resources over the next five years for research to help develop a more effective, universal influenza vaccine. In their letter, the Senators highlighted their efforts to secure $100 million in funding for research related to a universal influenza vaccine in the fiscal year 2018 appropriations bill that was signed into law in March.

“Seasonal influenza is a pressing public health threat, taking a substantial toll on our families, health care system, and economy each year. This season was particularly difficult, resulting in at least 160 pediatric deaths. Despite the damage inflicted by influenza annually, our current vaccine is only 60 percent effective at best. It is critical that we develop a more effective and longer lasting approach to preventing influenza,” the senators wrote.

This most recent flu season was particularly difficult in the United States, resulting in at least 160 pediatric deaths. The flu costs the nation $10.4 billion in direct medical costs annually and $87 billion in total economic burden.

In February, Klobuchar, Markey and Senator Tina Smith also sent a letter to the Department of Health and Human Services asking for more information on how the Department is preparing for and responding to the flu virus. Specifically, the senators requested additional detail on the Department’s work to predict more accurately the right viral strain for upcoming flu seasons, produce vaccines more rapidly and effectively, prepare hospitals and providers for the risks of a severe flu season, and protect all Americans against the virus through developing a universal flu vaccine. 

The full text of the letter can be found here:

Dear President Trump,

As lawmakers who have led efforts to support the creation of a universal influenza vaccine, we appreciate reports that you expressed strong interest in this issue in a recent meeting with Bill Gates. We urge you to support our legislation, the Flu Vaccine Act (S. 2438), which would authorize additional resources over the next five years for research to help develop a more effective, universal influenza vaccine.

Seasonal influenza is a pressing public health threat, taking a substantial toll on our families, health care system, and economy each year. This season was particularly difficult, resulting in at least 160 pediatric deaths. Despite the damage inflicted by influenza annually, our current vaccine is only 60 percent effective at best. It is critical that we develop a more effective and longer lasting approach to preventing influenza.

In February, we introduced our legislation to invest significant additional resources in research related to the development of a universal influenza vaccine. S. 2438 would authorize $1 billion to the National Institute of Allergy and Infectious Diseases (NIAID), the institute within the National Institutes of Health spearheading influenza research.

We also worked with our colleagues on the Senate Appropriations Committee to secure $100 million in funding and encourage NIAID to continue prioritizing research related to a universal influenza vaccine in the fiscal year 2018 appropriations bill you signed into law in March.

It is imperative that NIAIO and our federal agencies engaged in influenza-related research possess the resources needed to increase our understanding of the pathogenesis of influenza, the immune response to both influenza infection and vaccination, and different approaches to vaccination. This is particularly crucial now that NIAID recently initiated a Phase 2 clinical trial for a potential universal influenza vaccine candidate.

We are committed to working with your Administration so the goal of a universal influenza vaccine becomes a reality. We look forward to working together to eliminate seasonal influenza as a public health burden once and for all.

Sincerely,

###